Literature DB >> 3386386

Herpes zoster oticus: treatment with intravenous acyclovir.

J R Dickins1, J T Smith, S S Graham.   

Abstract

Herpes zoster oticus generally has a poor prognosis, leaving many patients with permanent facial nerve dysfunction. This preliminary report describes results in seven patients treated for zoster; all were given intravenous acyclovir. Patients were infused with 10 mg/kg every 8 hours over a 7-day hospitalization period. Five of the seven patients showed some return of facial function at the time of discharge. At follow-up, 4 patients had achieved a House grade I result, 1 patient a grade II, and 2 patients a grade III. Reasons for the differences in final results are discussed, along with a recommended regimen for treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3386386     DOI: 10.1288/00005537-198807000-00019

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Bell's Palsy and Herpes Zoster Oticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

2.  Ramsay Hunt Syndrome Treated with Oral Acyclovir.

Authors:  Yashpal Singh; Charanjit Singh
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Facial paralysis and lymphocytic facial neuritis in a rhesus macaque (Macaca mulatta) positive for simian retrovirus type D2.

Authors:  Anna L Hampton; Lesley A Colby; Ingrid L Bergin
Journal:  Comp Med       Date:  2011-12       Impact factor: 0.982

Review 4.  Optimum management of the discharging ear.

Authors:  J Ruddy; R C Bickerton
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 5.  Herpes zoster involving the abducens and vagus nerves without typical skin rash: A case report and literature review.

Authors:  Taesung Joo; Young Chan Lee; Tae Gi Kim
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Ramsay Hunt syndrome affecting the vagus nerve with epiglottic ulcers as the first manifestation: a case report.

Authors:  Jie Zhang; Xuemei Wei
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.